首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   70332篇
  免费   5974篇
  国内免费   3226篇
耳鼻咽喉   195篇
儿科学   1325篇
妇产科学   826篇
基础医学   12624篇
口腔科学   738篇
临床医学   5488篇
内科学   16502篇
皮肤病学   1070篇
神经病学   2637篇
特种医学   1283篇
外国民族医学   9篇
外科学   3834篇
综合类   10517篇
现状与发展   19篇
预防医学   5773篇
眼科学   470篇
药学   8759篇
  18篇
中国医学   3544篇
肿瘤学   3901篇
  2023年   744篇
  2022年   1286篇
  2021年   2268篇
  2020年   2111篇
  2019年   2368篇
  2018年   2254篇
  2017年   2224篇
  2016年   2591篇
  2015年   2853篇
  2014年   4655篇
  2013年   4848篇
  2012年   4778篇
  2011年   5087篇
  2010年   4108篇
  2009年   3912篇
  2008年   3867篇
  2007年   3757篇
  2006年   3426篇
  2005年   2926篇
  2004年   2421篇
  2003年   2101篇
  2002年   1705篇
  2001年   1496篇
  2000年   1156篇
  1999年   1010篇
  1998年   925篇
  1997年   767篇
  1996年   648篇
  1995年   661篇
  1994年   565篇
  1993年   462篇
  1992年   440篇
  1991年   349篇
  1990年   318篇
  1989年   285篇
  1988年   238篇
  1987年   205篇
  1986年   170篇
  1985年   443篇
  1984年   460篇
  1983年   371篇
  1982年   379篇
  1981年   316篇
  1980年   288篇
  1979年   261篇
  1978年   205篇
  1977年   159篇
  1976年   176篇
  1975年   153篇
  1974年   126篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
41.
《Vaccine》2020,38(10):2315-2325
In the preparation of glycoconjugate vaccines in clinical practice, two highly immunogenic carrier proteins, CRM197 and tetanus toxoid (TT), are predominantly conjugated with the capsular polysaccharides (CPSs) of bacterial pathogens. In addition, TT has long been used as an effective vaccine to prevent tetanus. While these carrier proteins play an important role in immunogenicity and vaccine design alike, their defined human major histocompatibility complex class II (MHCII) T cell epitopes are inadequately characterized. In this current work, we use mass spectrometry to identify the peptides from these carrier proteins that are naturally processed and presented by human B cells via MHCII pathway. The MHCII-presented peptides are screened for their T cell stimulation using primary CD4+ T cells from four healthy adult donors. These combined methods reveal a subset of eleven CD4+ T cell epitopes that proliferate and stimulate human T cells with diverse MHCII allelic repertoire. Six of these peptides stand out as potential immunodominant epitopes by responding in three or more donors. Additionally, we provide evidence of these natural epitopes eliciting more significant T cell responses in donors than previously published TT peptides selected from T cell epitope screening. This study serves toward understanding carrier protein immune responses and thus enables the use of these peptides in developing novel knowledge-based vaccines to combat persisting problems in glycoconjugate vaccine design.  相似文献   
42.
43.
目的:观察地黄饮子加减方对血管性痴呆模型大鼠学习记忆能力及海马CA1区神经元的影响。方法:将84只SD雄性大鼠,按随机原则选出12只大鼠作为假手术组,其余72只大鼠采用两血管阻断法制备血管性痴呆模型,筛选60只模型大鼠,每组12只,随机分为模型组,尼莫地平组(0. 011 g·kg~(-1)),地黄饮子加减方高、中、低(4. 54,2. 27,1. 14 g·kg~(-1))剂量组。连续灌胃30 d后,Morris水迷宫检测大鼠学习记忆能力,苏木素-伊红(HE)观察海马CA1区神经元形态结构改变,透射电镜观察海马CA1区神经元超微结构变化,原位细胞凋亡检测法(TUNEL)检测海马CA1区细胞凋亡水平,免疫组化(IHC)检测海马CA1区组织磷脂酰肌醇3-激酶(PI3K),蛋白激酶B(Akt),半胱氨酸蛋白酶-3(Caspase-3)表达水平。结果:与假手术组比较,模型组大鼠逃避潜伏期显著延长,穿越原平台次数显著减少(P 0. 01),海马CA1区神经元形态均有不同程度地损伤,凋亡率显著增加(P 0. 01),PI3K,Akt的积分吸光度和平均积分吸光度明显降低(P 0. 01),Caspase-3的积分吸光度和平均积分吸光度显著增高(P 0. 01);与模型组比较,各给药组大鼠逃避潜伏期缩短(P 0. 05,P 0. 01),穿越原平台次数增加(P 0. 05,P 0. 01),PI3K,Akt的积分吸光度和平均积分吸光度值显著增高(P 0. 01),Caspase-3的积分光密度和平均积分吸光度不同程度降低(P 0. 05,P 0. 01)。结论:地黄饮子加减方可改善血管性痴呆模型大鼠学习记忆能力和海马CA1区神经元损伤,潜在机制可能与PI3K/Akt信号转导途径的激活,抑制大鼠海马CA1区神经细胞的凋亡有关。  相似文献   
44.
《Molecular immunology》2015,63(2):296-304
Regulatory B cells (Bregs) are defined by their ability to restrain inflammatory responses both in vivo and in vitro. Interleukin 10 (IL-10) production by Bregs is thought to be central to their ability to regulate inflammation, largely due to IL-10s’ ability to suppress pro-inflammatory cytokine production by effector lymphocytes and to maintain the differentiation of regulatory T cells (Tregs). However, with an increase in available published data, it has become evident that Bregs utilize a number of suppressive mechanisms in order to alter the activation of a variety of different lymphocytes. Here, we summarize the multiplicity of cellular targets of Breg-mediated suppression and describe the mechanisms employed by Bregs to suppress chronic inflammatory responses.  相似文献   
45.
ObjectiveIn this study, we used HepG2 human hepatocellular carcinoma cells to study the effects of Compound Xishu Granule (CXG) on cell proliferation, apoptosis, and the cell cycle in vitro. We also used a xenograft tumor model to study the anti-tumor effects of CXG and related mechanisms in vivo.MethodsThe effect of CXG on cell viability was measured using Cell Counting Kit-8 and a colony formation assay. The effect of CXG on apoptosis and the cell cycle was analyzed using flow cytometry. The in vivo anti-tumor effect of CXG was assessed by measuring the volume change in xenograft tumors after drug administration. The CXG anti-tumor mechanism was studied using western blotting assay to detect cell cycle and apoptotic associated proteins.ResultsCXG suppressed HepG2 cell proliferation in a time- and dose-dependent manner in vitro. Colony formation experiments showed that CXG administration for 24 h significantly reduced HepG2 cell formations (P < .01). Flow cytometric analysis showed that CXG treatment for 48 h promoted apoptosis and blocked HepG2 cells in the G2/M phase. Western blotting results showed that Bax was significantly up-regulated and Bcl-2 was down-regulated in graft tumor tissues and HepG2 cells after CXG administration, which increased the Bax/Bcl-2 ratio. PLK1, CDC25C, CDK1, and Cyclin B1 expression were up-regulated. CXG had a good inhibitory effect on graft tumor growth in vivo.ConclusionCXG has good anti-tumor effects in vitro and in vivo. In vitro, CXG promoted HepG2 cell apoptosis and induced G2/M phase arrest. In vivo, CXG significantly inhibited graft tumor growth. The CXG mechanism in treating hepatocellular carcinoma may be that CXG can induce abnormal apoptotic and cell cycle associated protein expression, leading to mitotic catastrophe and apoptosis.  相似文献   
46.
程佳慧  武倩  刘喜纲 《中成药》2020,(3):570-573
目的制备葫芦素B固体分散体。方法溶剂法制备固体分散体后,以溶出度为评价指标筛选药物-载体(PVP K30)比例。扫描电子显微镜(SEM)、傅里叶变换红外光谱(FTIR)、差示扫描量热(DSC)、X射线衍射(XRD)进行表征。结果药载比为1∶11时,60 min内溶出度为62.01%。葫芦素B可能以无定形状态分散于载体中。结论该方法简便可行,葫芦素B制成固体分散体后体外溶出度明显提高。  相似文献   
47.
48.
[目的] 优选复方夏枯草洗剂的提取工艺。[方法] 采用L9(34)正交设计,以迷迭香酸、丹酚酸B的含量及出膏率的综合评分为指标,考察料液比、提取时间、提取次数对提取效果的影响,优选复方夏枯草洗剂的最佳提取工艺。[结果] 根据综合评分的结果,优选出最佳提取工艺为加8倍水,提取3次,每次0.5 h。[结论] 该工艺准确可靠,可行性好。  相似文献   
49.
Inflammation plays a critical role in the development of ventilator-induced lung injury (VILI). Endoplasmic reticulum (ER) stress is associated with a variety of diseases through the modulation of inflammatory responses. However, little is known about how ER stress is implicated in VILI. In this study, murine mechanical ventilation models were constructed. Total protein and inflammatory cytokines were measured in bronchoalveolar lavage fluid (BALF), and lung tissue injury was assessed by histology. Our data revealed that mice subjected to high tidal ventilation (TV) for 4 h showed more severe pulmonary edema and inflammation than those of mice with spontaneous breathing and low TV-treatment. In addition, the high TV-treated animals upregulated the ER stress markers GRP78, CHOP, p-IRE1α, TRAF2, and p-NF-κB expression at both the mRNA and protein levels in lung tissue. Administration of thapsigargin exacerbated the histological changes, inflammation and expression of GRP78 and CHOP after high TV, but treatment with ER stress and IRE1α kinase inhibitors attenuated the pathological damage and downregulated the high expression of GRP78, CHOP, p-IRE1α, TRAF2, and p-NF-κB, suggesting that ER stress is involved in VILI though the IRE1α/TRAF2/NF-κB signaling pathway in mice.  相似文献   
50.
Tirabrutinib is a second‐generation Bruton’s tyrosine kinase inhibitor with greater selectivity than ibrutinib. Here, we conducted a multicenter, phase II study of tirabrutinib in patients with treatment‐naïve (Cohort A) or with relapsed/refractory (Cohort B) Waldenström’s macroglobulinemia (WM). Patients were treated with tirabrutinib 480 mg once daily. The primary endpoint was major response rate (MRR; ≥ partial response). Secondary endpoints included overall response rate (ORR; ≥ minor response), time to major response (TTMR), progression‐free survival (PFS), overall survival (OS), and safety. In total, 27 patients (18 in Cohort A; 9 in Cohort B) were enrolled. The median age was 71 y, and the median serum immunoglobulin M level was 3600 mg/dL. Among the patients, 96.2% had the MYD88L265P mutation. MRR and ORR were 88.9% and 96.3%, respectively (Cohort A: MRR, 88.9%; ORR, 94.4%; Cohort B: MRR, 88.9%; ORR, 100%). Median TTMR was 1.87 mo. PFS and OS were not reached with a median follow‐up of 6.5 and 8.3 mo for Cohorts A and B, respectively. The most common adverse events (AEs) were rash (44.4%), neutropenia (25.9%), and leukopenia (22.2%), with most AEs classified as grade 1 or 2. Grade ≥ 3 AEs included neutropenia (11.1%), lymphopenia (11.1%), and leukopenia (7.4%). No grade 5 AEs were noted. All bleeding events were grade 1; none were associated with drug‐related atrial fibrillation or hypertension. Although the follow‐up duration was relatively short, the study met the primary endpoint. Therefore, tirabrutinib monotherapy is considered to be highly effective for both untreated and relapsed/refractory WM with a manageable safety profile. (JapicCTI‐173646).  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号